Detalhe da pesquisa
1.
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Gynecol Oncol
; 153(1): 127-134, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30686551
2.
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.
Proc Natl Acad Sci U S A
; 113(21): 6005-10, 2016 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27152024
3.
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lancet Oncol
; 19(2): 207-215, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29361470
4.
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Gynecol Oncol
; 148(2): 281-285, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29233532
5.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
6.
Tumor Regulation of Lymph Node Lymphatic Sinus Growth and Lymph Flow in Mice and in Humans.
Yale J Biol Med
; 90(3): 403-415, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28955180
7.
Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
Gynecol Oncol
; 143(2): 389-392, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27575909
8.
Genetic characterization of early onset ovarian carcinoma.
Gynecol Oncol
; 140(2): 221-5, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26718727
9.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Gynecol Oncol
; 143(2): 379-388, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27614696
10.
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Proc Natl Acad Sci U S A
; 110(42): 17041-6, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24085845
11.
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
Gynecol Oncol
; 128(3): 483-7, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23262210
12.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Cancer Res
; 81(18): 4709-4722, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34321239
13.
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program.
J Exp Med
; 198(5): 705-13, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12953092
14.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov
; 9(2): 210-219, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425037
15.
Lymph node mapping in the mouse.
J Immunol Methods
; 332(1-2): 170-4, 2008 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18164026
16.
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Nat Commun
; 9(1): 1849, 2018 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748565
17.
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Nat Commun
; 9(1): 3970, 2018 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30266954
18.
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
Clin Cancer Res
; 24(4): 777-783, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191972
19.
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Clin Cancer Res
; 24(4): 744-752, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29138343
20.
Exploring the Pregnant Guinea Pig as a Model for Group B Streptococcus Intrauterine Infection.
J Infect Dis Med
; 2(2)2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29034376